IP Library › Granted Patent US 12,594,438
Granted Patent B2
US 12,594,438 · App. 18/389,933 · Granted Apr 7, 2026

Bronchial denervation using integrated a-mode signal for optimization of ultrasound treatment

Inventors: Reinhard J. Warnking (Westlake, FL); Satoshi Nishiaoki (Setauket, NY)
Assignee: AerWave Medical, Inc.
A61N7/00A61B8/085A61B8/12A61B8/429A61N7/022A61B1/00082A61N2007/0004A61N2007/003A61N2007/0043A61N2007/0052A61N2007/0082
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,594,438
App. No.
18/389,933
Granted
Apr 7, 2026
Kind
B2
Abstract

Apparatus and methods for deactivating bronchial nerves extending along a bronchial branch of a mammalian subject to treat asthma and related conditions. An ultrasonic transducer ( 11 ) is inserted into the bronchus as, for example, by advancing the distal end of a catheter ( 10 ) bearing the transducer into the bronchial section to be treated. The ultrasonic transducer emits focused ultrasound so as to heat tissues throughout circular impact volume ( 13 ) as, for example, at least about 1 cm 3 encompassing the bronchus to a temperature sufficient to inactivate nerve conduction but insufficient to cause rapid ablation or necrosis of the tissues. The treatment can be performed without locating or focusing on individual bronchial nerves.

Claims (24)

1 . A system for inactivating bronchial nerve conduction in a mammalian subject, comprising:

an elongated member supporting an ultrasound transducer adapted for insertion into a bronchial branch of a bronchial tree of the mammalian subject, the ultrasound transducer configured to transmit ultrasound energy in a first mode and in a second mode; and

a control configured to control the transducer, the control adapted to a) control the ultrasound transducer to i) transmit ultrasound energy at a sub-therapeutic level for a diagnostic function in the first mode; ii) analyze circumferential A-mode ultrasound echoes from the transmitted ultrasound energy for the diagnostic function; and iii) process the A-mode ultrasound echoes to A-mode signals integrated over a treatment volume for the diagnostic function; and #) b) control the transducer to transmit ultrasound energy in a therapeutic function in the second mode so that the ultrasound energy is applied at a therapeutic level sufficient to inactivate conduction of bronchial nerves, the therapeutic level being below a level required for tissue necrosis.

2 . The system of claim 1 , wherein the control transmits ultrasound energy in the first mode to receive volume integrated ultrasound echoes to measure a diameter of the bronchial branch.

3 . The system of claim 2 , wherein the signals to measure the diameter is delivered in a low-power ultrasound pulse.

4 . The system of claim 2 , wherein the control is configured to adjust power settings of ultrasound based on the diameter of the bronchial branch.

5 . The system of claim 1 , wherein the system further comprises at least one pressure sensor to monitor liquid flow through the catheter and determine a diameter of the bronchial branch.

6 . The system of claim 1 , wherein the elongated member comprises a catheter having a balloon and the transducer is positioned within the balloon, the balloon containing a circulating cooling fluid.

7 . The system of claim 1 , wherein the elongated member comprises a catheter having a balloon and the transducer transmits energy in a 360 degree cylindrical pattern and the control detects whether circumferential contact of the balloon with the bronchial branch is complete or partial.

8 . The system of claim 1 , wherein the elongated member comprises a catheter having a balloon, wherein the control is configured to deliver ultrasound energy encompassing 360 degrees about a proximal to distal dimension of the transmitter.

9 . The system of claim 1 , wherein analysis of a return signal of a transmitted pulse in the first mode determines a circular or non-circular structure of the bronchial lumen.

10 . The system of claim 1 , wherein the control is configured to interleave pulses in the first mode and in the second mode to monitor progress in real time.

11 . The system of claim 1 , wherein the control unit is configured to determine position of cartilage rings based on ultrasound reflected in the first mode, and the elongated member is positioned to minimize a portion of the ultrasound reflection by cartilage rings and the control is configured to transmit ultrasound energy in the therapeutic mode to direct the ultrasound energy between the cartilage rings.

12 . The system of claim 1 , wherein the elongated member has a balloon and the transducer is movable inside the balloon for positioning between cartilage rings.

13 . The system of claim 1 , wherein the transducer comprises a plurality of transducer elements activatable individually or in combination.

14 . The system of claim 1 , wherein power adjustment is based on a determined diameter of a bronchial branch.

15 . The system of claim 14 , wherein the control transmits ultrasound energy in the first mode to generate a signal and process the A-mode ultrasound echoes to measure the diameter of the bronchial branch.

16 . A system for inactivating bronchial nerve conduction in a mammalian subject, comprising:

an elongated member supporting an ultrasound transducer adapted for insertion into a bronchial branch of a bronchial tree of the mammalian subject, the ultrasound transducer configured to transmit ultrasound energy in a first mode and in a second mode; and

a control configured to control the transducer, the control adapted to control the ultrasound transducer to i) transmit ultrasound energy at a sub-therapeutic level for a diagnostic function in the first mode; and ii) transmit ultrasound energy in a therapeutic function in the second mode so that the ultrasound energy is applied at a therapeutic level sufficient to inactivate conduction of bronchial nerves, the therapeutic level being below a level required for tissue necrosis,

wherein the elongated member comprises a catheter having a balloon and the transducer is positioned within the balloon, and the system is configured to determine the diameter of the bronchial branch by detecting a pressure increase in relation to volume increase of the balloon.

17 . The system of claim 16 , wherein the diameter of the bronchial branch is determined through a look up table in a memory connected to the control, the look up table relating volume/pressure values with diameters.

18 . The system of claim 16 ,

wherein the elongated member has a balloon, a cooling fluid within the balloon, and the transducer within the balloon.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 20, 2023
From: WARNKING, REINHARD J.; NISHIAOKI, SATOSHI
To: AERWAVE MEDICAL, INC.
Reel/Frame 066089/0772 →
Continuity (3)
Continuation 17418545
Provisional Application 63002555 · Mar 31, 2020
Related Publication 20240123262A1 · Apr 18, 2024
References Cited (57)
US 6984993B2 · Ariav · 2006 [cited by applicant]
US 8425455B2 · Nentwick · 2013 [cited by applicant]
US 8992447B2 · Gertner · 2015 [cited by applicant]
US 10828462B2 · Daniels et al. · 2020 [cited by applicant]
US 11020618B1 · Warnking · 2021 [cited by applicant]
US 11273330B2 · Warnking · 2022 [cited by applicant]
US 11278313B2 · Warnking · 2022 [cited by applicant]
US 11446524B2 · Mayse et al. · 2022 [cited by applicant]
US 11565135B2 · Warnking · 2023 [cited by examiner]
US 11607568B2 · Warnking · 2023 [cited by examiner]
US 20030060813A1 · Loeb · 2003 [cited by applicant]
US 20030078645A1 · Pigott · 2003 [cited by applicant]
US 20030191392A1 · Haldeman · 2003 [cited by applicant]
US 20050222558A1 · Baxter · 2005 [cited by applicant]
US 20080287837A1 · Makin · 2008 [cited by applicant]
US 20110144491A1 · Sliwa · 2011 [cited by applicant]
US 20110245665A1 · Nentwick · 2011 [cited by applicant]
US 20110257523A1 · Hastings et al. · 2011 [cited by applicant]
US 20110257561A1 · Gertner · 2011 [cited by applicant]
US 20120143099A1 · Daniels et al. · 2012 [cited by applicant]
US 20130103028A1 · Tsoref · 2013 [cited by applicant]
US 20130197555A1 · Schaer et al. · 2013 [cited by applicant]
US 20130281889A1 · Gertner · 2013 [cited by applicant]
US 20140031727A1 · Warnking · 2014 [cited by applicant]
US 20160008636A1 · Warnking · 2016 [cited by applicant]
US 20160113699A1 · Sverdlik · 2016 [cited by applicant]
US 20160220851A1 · Mayse · 2016 [cited by applicant]
US 20160287912A1 · Warnking · 2016 [cited by examiner]
US 20170014159A1 · Stokes · 2017 [cited by applicant]
US 20180146839A1 · Friedlander et al. · 2018 [cited by applicant]
US 20200238085A1 · Khodaparast · 2020 [cited by applicant]
US 20200246069A1 · Rioux et al. · 2020 [cited by applicant]
US 20210316161A1 · Warnking et al. · 2021 [cited by applicant]
US 20220008753A1 · Warnking et al. · 2022 [cited by applicant]
US 20230009916A1 · Mayse · 2023 [cited by examiner]
US 20240366967A1 · Warnking · 2024 [cited by examiner]
EP 1159036 · 2007 [cited by applicant]
EP 2521593 · 2015 [cited by applicant]
WO WO2007009118 · 2007 [cited by applicant]
WO WO2011053757 · 2011 [cited by applicant]
WO WO2012120495 · 2012 [cited by applicant]
WO WO2013048912 · 2013 [cited by applicant]
WO WO2014022777 · 2014 [cited by applicant]
WO WO2015066424 · 2015 [cited by applicant]
WO WO2021201963 · 2021 [cited by applicant]
Armitage, L., & Rachel, B. (Jun. 22, 2020). Inhaled corticosteroids: A rapid review of the evidence for treatment or prevention of COVID-19. Retrieved Aug. 20, 2020, from https://www.cebm.net/covid-19/inhaled-corticoste… [cited by applicant]
Buehler, Markus J. “Nanomechanical sonification of the 2019-nCoV coronavirus spike protein through a materiomusical approach.” Apr. 2, 2020, https://web.archive.org/web/20200402064158/hllps://arxiv.org/ftp/arxiv/papers/… [cited by applicant]
M. C. (Apr. 24, 2020). Turning up the heat on COVID-19: Heat as a therapeutic intervention. Retrieved Aug. 20, 2020, from https://f1 000research .com/articles/9-292/v1 (Year: 2020). [cited by applicant]
Marcela, M. (May 18, 2020). The Use of Core Warming as a Treatment for Coronavirus Disease 2019 (COVID-19): An Initial Mathematical Model. Retrieved Aug. 20, 2020, from https://jca.emnuvens.com.br/jca/article/view/3382/… [cited by applicant]
Nuvaira. “Minimally Invasive Procedure for COPD Treatment.” Nuvaira, Dec. 26, 2019, web.archive.org/web/20191226085420/www.nuvaira.com/the-procedure/. Accessed Apr. 2, 2021. (Year: 2019). [cited by applicant]
Q&A: Dexamethasone and COVID-19. (Jun. 25, 2020). Retrieved Aug. 20, 2020, from https://www.who.int/news-room/q-a-detail/q-a-dexamethasone-and-covid-19 (Year: 2020). [cited by applicant]
Xu, Z., et al. (Feb. 18, 2020). Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Retrieved Aug. 20, 2020, from https://www.sciencedirect.com/science/article/pii/S221326002030076X?vi… [cited by applicant]
Zurn, R. (May 28, 2020). Ultrasound may prove to be effective, noninvasive treatment for COVID-19. Retrieved Aug. 20, 2020, from https://cse.umn.edu/college/feature-stories/ultrasound-may-prove-be-effective-noninvasive-… [cited by applicant]
PCT/US2021/015825 International Search Report dated Apr. 29, 2021. [cited by applicant]
EP 21779200 Search Report dated Mar. 27, 2024. [cited by applicant]
PCT/US2023/034610 International Search Report dated Mar. 13, 2024. [cited by applicant]
PCT/US2023/034606 International Search Report dated Apr. 19, 2024. [cited by applicant]